Jay Patel
Nephrology · Greensboro, NCNPI 1013034727
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,949 of the $26,505 with a category attached, or 60.2%. 37 manufacturers reported payments, led by Bayer at 58.6% of the total. Reporting peaked in 2022 at $14,810 and has fallen 86.7% since, to $1,975 in 2025. Among nephrology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 510 payments — averaging $51.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$16K
- Amgen$3K
- AstraZeneca$2K
- Mallinckrodt Hospital Products Inc.$1K
- Otsuka America Pharmaceutical, Inc.$872
- Vifor Pharma, Inc.$709
- plus $4K from 31 others
What the payments were for
- Consulting fees$260%
- Speaking & faculty fees$15,94960%
- Travel & lodging$580%
- Food & beverage$10,14138%
- Education$3321%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 38 | $15,540 |
| Amgen(2 entities) | 74 | $2,697 |
| AstraZeneca(2 entities) | 94 | $1,664 |
| Mallinckrodt Hospital Products Inc. | 33 | $1,066 |
| Otsuka America Pharmaceutical, Inc. | 43 | $872 |
| Vifor Pharma, Inc. | 39 | $709 |
| Travere Therapeutics, Inc. | 27 | $578 |
| Calliditas Therapeutics US Inc. | 16 | $457 |
| GSK | 23 | $391 |
| ANI Pharmaceuticals, Inc. | 17 | $277 |
| Mallinckrodt Enterprises LLC | 8 | $225 |
| Daiichi Sankyo Inc. | 10 | $198 |
| Novo Nordisk | 12 | $190 |
| Aurinia Pharma U.S., Inc. | 8 | $184 |
| Fresenius USA Marketing, Inc. | 11 | $179 |
| Novartis | 9 | $178 |
| Nxstage Medical, Inc. | 3 | $151 |
| AbbVie | 1 | $125 |
| OPKO Pharmaceuticals, LLC | 8 | $120 |
| Ardelyx, Inc. | 6 | $118 |
| Scpharmaceuticals Inc. | 5 | $112 |
| Medtronic | 2 | $73 |
| Alnylam Pharmaceuticals Inc. | 2 | $53 |
| Boehringer Ingelheim | 3 | $47 |
| Akebia Therapeutics Inc | 2 | $39 |
| AMAG Pharmaceuticals, Inc. | 3 | $37 |
| Sanofi | 2 | $33 |
| Boston Scientific | 2 | $33 |
| Mozarc Medical US LLC | 1 | $23 |
| Shire North American Group Inc | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Genentech USA, Inc. | 1 | $19 |
| Apellis Pharmaceuticals, Inc. | 1 | $18 |
| Pfizer | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| La Jolla Pharmaceutical Company | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,505 in reported general payments places this provider in the 90th percentile of 366 nephrology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JynarqueTolvaptan | 13 | $246,071 |
| FarxigaDapagliflozin Propanediol | 126 | $89,827 |
| VelphoroSucroferric Oxyhydroxide | 15 | $44,744 |
| AuryxiaFerric Citrate | 14 | $30,308 |
| VeltassaPatiromer Calcium Sorbitex | 23 | $19,624 |
| KerendiaFinerenone | 16 | $17,914 |
| JardianceEmpagliflozin | 27 | $15,519 |
| Sevelamer Carbonate | 37 | $6,988 |
| Cinacalcet Hcl | 18 | $1,340 |
| Torsemide | 47 | $1,275 |
| Furosemide | 186 | $1,263 |
| Calcitriol | 83 | $1,089 |
| Olmesartan Medoxomil | 101 | $1,086 |
| Amlodipine Besylate | 114 | $1,057 |
| Allopurinol | 76 | $861 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Jynarque | $872 | $246,07113 claims |
| AstraZenecaFarxiga | $1,664 | $89,827126 claims |
| Fresenius USA Marketing, Inc.Velphoro | $179 | $44,74415 claims |
| Akebia Therapeutics IncAuryxia | $39 | $30,30814 claims |
| BayerKerendia | $15,540 | $17,91416 claims |
| Boehringer IngelheimJardiance | $47 | $15,51927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 366 nephrology providers in North Carolina.
Other nephrology in Greensboro
- Joseph ColadonatoGreensboro$21K
- Dron BhandariGreensboro$8K
- Kellie GoldsboroughGreensboro$7K
- Samuel PeeplesGreensboro$6K
- Vikas SinghGreensboro$6K
- Gregory GreenwoodWinston-Salem$947K
- Michael EtomiCharlotte$212K
- William KendrickGreenville$125K
- Jason EckelCary$123K
- Raven VooraSanford$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.